1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

 
• By Joseph Haas

As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.

Liver

Gilead Sciences Inc.’s announcement at the J.P. Morgan Healthcare Conference that it will take its lead candidate for non-alcoholic steatohepatitis, the apoptosis signal-regulating kinase-1 (ASK1) inhibitor selonsertib, into Phase III soon is shaking up the NASH race.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D